Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 12/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534870 | 0.91 | AVPR2 (0.48) | AVPR2AVPR1AROCK2ROCK1 | |
| SCHEMBL3536010 | 0.91 | AVPR2 (0.47) | AVPR2AVPR1A | |
| SCHEMBL3536401 | 0.90 | AVPR2 (0.46) | AVPR2AVPR1AROCK2ROCK1 | |
| SCHEMBL3537560 | 0.88 | AVPR2 (0.50) | AVPR2AVPR1AROCK2ROCK1 | |
| SCHEMBL3534647 | 0.88 | ROCK2 (0.46) | AVPR2AVPR1AROCK2ROCK1 | |
| SCHEMBL3533374 | 0.87 | AVPR2 (0.47) | AVPR2AVPR1A | |
| SCHEMBL3534697 | 0.86 | AVPR2 (0.47) | AVPR2AVPR1A | |
| SCHEMBL3533432 | 0.86 | AVPR2 (0.47) | AVPR2AVPR1AROCK2ROCK1 | |
| SCHEMBL3535538 | 0.85 | MAPT (0.47) | AVPR2AVPR1AROCK2ROCK1 | |
| SCHEMBL5891149 | 0.85 | AVPR2 (0.46) | AVPR2AVPR1AROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691848-B2 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2010-04-06 | — | — | US | claimed |
| US-20060199806-A1 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-09-07 | — | — | US | claimed |
| US-7691848-B2 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2010-04-06 | — | — | US | disclosed |
| US-20060199806-A1 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199806-A1 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | FSHR, GNRHR, LHCGR | AVPR2 31/4885AVPR1A 63/4885KCNK3 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.